Sustained release formulations for the treatment of intraocular pressure of glaucoma
Inventors
Wong, Vernon G. • Hu, Mae W. • Huang, Glenn T.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9283231-B2
Publication Date
2016-03-15
Expiration Date
Abstract
The present embodiments provide for methods of treating elevated intraocular pressure or glaucoma using a sustained release medicament consisting of prostaglandin in benzyl benzoate that is injected intraocularly no more frequently than once every two months.
Core Innovation
The invention relates to a method of treating elevated intraocular pressure or glaucoma in a subject by administering, via intraocular injection, a unit dose of a liquid formulation into the vitreous or anterior chamber. The liquid formulation consists of about 0.1% to 5% prostaglandin in benzyl benzoate (w/w), and the unit dose is 5 μL to 60 μL inclusive.
The method provides sustained release of the prostaglandin after infrequent intraocular administration. The dosing frequency is no more frequently than once every two months, including schedules extending to once every twelve months as described, and the release duration is correlated with prostaglandin concentration and unit dose volume.
The disclosure is illustrated with a prostaglandin analog, notably latanoprost. Detection of latanoprost acid in aqueous or vitreous is reported to persist for extended periods, and in vivo data are described as showing reduced intraocular pressure over extended durations.
Claims Coverage
The partial content identifies one independent claim. It is directed to an intraocular injection treatment using a liquid prostaglandin formulation in benzyl benzoate with specific unit dose limits and an infrequent dosing interval, yielding sustained reduction of elevated intraocular pressure or glaucoma.
Intraocular injection into vitreous or anterior chamber of a unit dose liquid prostaglandin formulation in benzyl benzoate
Treating elevated intraocular pressure or glaucoma by administering by intraocular injection into the vitreous or anterior chamber a unit dose of 5 μL to 60 μL, inclusive, of a liquid formulation consisting of about 0.1% to 5% prostaglandin in benzyl benzoate (w/w), inclusive.
No more frequently than once every two months dosing interval
Administering the unit dose no more frequently than once every two months.
Across the identified independent claim, the core coverage is an intraocular injection into the vitreous or anterior chamber of a liquid formulation containing about 0.1% to 5% prostaglandin in benzyl benzoate, using a 5 μL to 60 μL unit dose, with administration no more frequently than once every two months.
Stated Advantages
Sustained release medicament and extended duration of therapeutic effect are described for the intraocular treatment.
Reduced intraocular pressure is reported for extended periods.
Ocular/toxicity tolerability is indicated in the disclosure.
Documented Applications
Treating elevated intraocular pressure or glaucoma in a subject in need of such treatment by intraocular injection into the vitreous or anterior chamber using a liquid prostaglandin formulation in benzyl benzoate.
Interested in licensing this patent?